New Bench to Bedside now online: Messenger RNA vaccines against SARS-CoV-2. The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF on Cell.

https://www.cell.com/cell/fulltext/S0092-8674(20)31761-X